Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

Ovarian Cancer Clinical Trial

Official title:

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03490669
• Other study ID #: MSC-1-101
• Secondary ID: 2017-003320-79
• Status: Completed
• Phase: Phase 1
• Start date: May 21, 2018
• Est. completion date: September 23, 2019

Study information

• Verified date: April 2024
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a 2-part study to evaluate the safety and antitumor activity of MSC-1. MSC-1 is a first-in-class, humanized monoclonal antibody (IgG1) which binds to the immunosuppressive human cytokine Leukemia Inhibitory Factor (LIF), and is intended to treat adult patients with Advanced Solid Tumors.

In part 1, multiple dose levels of MSC-1 in patients with advanced solid tumors will be studied to determine the recommended dose for further evaluation of safety and efficacy in Part 2.

Description:

MSC-1 is a first-in-class, humanized monoclonal antibody (IgG1) which binds to the immunosuppressive human cytokine Leukemia Inhibitory Factor (LIF), and is intended to treat adult patients with advanced solid tumors. LIF is a pleiotropic cytokine involved in many physiological and pathological processes including the promotion of an immunosuppressive environment. In cancer, it is hypothesized that LIF expressing malignancies co-opt this activity, creating an immunosuppressive tumor microenvironment as well as promoting the activity of cancer-initiating cell(s) (CICs). LIF is highly expressed in a subset of tumors across multiple solid tumor types.

During dose escalation, patients with advanced solid tumors will be treated with MSC-1 with the primary objective of determining the safety and tolerability of MSC-1 and defining an appropriate dose for further evaluation in dose expansion. MSC-1 will be administered intravenously (IV) until disease progression, unmanageable toxicity, withdrawal of consent or study termination.

In dose expansion, up to 4 parallel cohorts of patients with LIF-High tumors (NSCLC, Ovarian Cancer, Pancreatic Cancer), and a cohort of mixed solid tumors (referred to as the "basket cohort"), may be treated at the recommended expansion dose to further characterize the safety, tolerability, PK, PD and anti-tumor activity of MSC-1.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: September 23, 2019
• Est. primary completion date: September 23, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria (All patients):

• Confirmed Advanced Unresectable Solid Tumor

• Measurable disease by RECIST 1.1 by CT or MRI

• Documented disease progression on or following last line of therapy

• Archival tumor sample for submission

• ECOG performance status 0 or 1

• Resolution of all acute, reversible toxic effects of prior therapy or surgical procedures to at least grade 1 (except alopecia and peripheral neuropathy to at least grade 2)

• Adequate organ function

• A limited number of patients enrolled in Dose Escalation may be required to agree to pre- and on-treatment tumor biopsies

Inclusion Criteria (Dose Expansion patients only)

• LIF- High NSCLC, Ovarian Cancer, or Pancreatic Cancer for the tumor-specific cohorts or Advanced Solid Tumor for the basket cohort as assessed by tumor tissue evaluation by IHC

• All patients enrolled in Dose Expansion must agree to undergo pre- and on-treatment tumor biopsies

Exclusion Criteria (All Patients):

• Systemic anti-cancer therapy within 4 weeks or 5 half-lives prior to study entry

• Previous or concurrent malignancy that could affect compliance with protocol or interpretation of results

• Clinically significant, unstable cardiovascular or pulmonary disease as specified in detail in the study protocol

• History of acquired or congenital immunodeficiency syndrome or receiving immunosuppressive therapy

• Uncontrolled infections or serologically positive HIV or hepatitis B or C infection

• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase risk associated with study participation or interfere with interpretation of study results

Related Conditions & MeSH terms

• Advanced Solid Tumors
• Non Small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer

Intervention

Biological:
• MSC-1
humanized monoclonal antibody for intravenous administration

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Center	Toronto	Ontario
Spain	Hospital Universitario Vall d'Hebron	Barcelona
United States	START MidWest	Grand Rapids	Michigan
United States	Memorial Sloan Kettering Cancer Center- Westchester	Harrison	New York
United States	Memorial Sloan Kettering Cancer Center- Monmouth	Middletown	New Jersey
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	HonorHealth	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  Canada,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the safety and tolerability of MSC-1 and determine the recommended dose for MSC-1 monotherapy for further evaluation in the expansion part of the study	Assessment of frequency & severity of adverse events	Patients will be evaluated for approximately 6 months or until disease progression
Primary	Assess the preliminary anti-tumor activity of MSC-1 monotherapy	Determine objective response rate (ORR)	Patients will be evaluated for approximately 6 months or until disease progression
Secondary	Confirm safest dose of MSC-1 for further study	Assessment of adverse events	Patients will be evaluated for approximately 6 months or until disease progression
Secondary	Characterize the PK of MSC-1	Serum levels of MSC-1	Patients will be evaluated before and after each dose of MSC-1 for approximately 6 months or until disease progression. PK will be evaluated more frequently for the first 2 cycles of treatment

External Links

•   CSR Synopsis
•   Sponsor Website